Price
$45.98
Increased by +0.09%
Dollar Volume (20D)
44.8 M
ADR%
6.12
Earnings Report Date (estimate)
May 3, 24
Shares Float
55.75 M
Shares Outstanding
68 M
Shares Short
7.77 M
Market Cap.
3.12 B
Beta
1.97
Price / Earnings
N/A
20D Range
42.62 53.08
50D Range
35.37 53.08
200D Range
13.57 53.08
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Feb 27, 24 -2.53
Decreased by -62.41%
-1.27
Decreased by -99.5%
Nov 7, 23 -1.18
Increased by +4.84%
-1.58
Increased by +25.32%
Aug 8, 23 -1.25
Increased by +5.3%
-1.65
Increased by +24.24%
May 5, 23 -1.54
Decreased by -28.33%
-1.51
Decreased by -1.99%
Feb 23, 23 -1.56
Decreased by -56%
-1.22
Decreased by -27.87%
Nov 8, 22 -1.24
Decreased by -31.91%
-1.13
Decreased by -9.73%
Aug 4, 22 -1.32
Decreased by -28.16%
-1.04
Decreased by -26.92%
May 5, 22 -1.2
Decreased by -42.86%
-0.89
Decreased by -34.83%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 34.6 M
Increased by +14.19%
-64 M
Increased by +3.32%
Decreased by -184.97%
Increased by +15.34%
Jun 30, 23 54.5 M
Increased by +74.12%
-66.6 M
Increased by +4.86%
Decreased by -122.2%
Increased by +45.36%
Mar 31, 23 32.5 M
Increased by +34.3%
-80.8 M
Decreased by -27.44%
Decreased by -248.62%
Increased by +5.1%
Dec 31, 22 38 M
Increased by +44.49%
-79.9 M
Decreased by -50.75%
Decreased by -210.26%
Decreased by -4.34%
Sep 30, 22 30.3 M
Increased by +226.34%
-66.2 M
Decreased by -41.6%
Decreased by -218.48%
Increased by +56.61%
Jun 30, 22 31.3 M
Increased by +464.53%
-70 M
Decreased by -39.2%
Decreased by -223.64%
Increased by +75.34%
Mar 31, 22 24.2 M
Increased by +336.87%
-63.4 M
Decreased by -54.77%
Decreased by -261.98%
Increased by +64.57%
Dec 31, 21 26.3 M
Increased by +1.09 K%
-53 M
Decreased by -27.57%
Decreased by -201.52%
Increased by +89.24%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.